The Alliance for Regenerative Medicine (ARM) Releases Agenda For 2016 Cell & Gene Meeting On The Mesa

WASHINGTON, DC--(Marketwired - September 07, 2016) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, today released the agenda for its upcoming three-day Cell & Gene Meeting on the Mesa annual conference, October 5-7, 2016.

Organized by ARM and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is three-day conference featuring three distinct parts, the program's two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.

The event's Partnering Forum, held October 5-6, features more than 50 speakers. Panelists will present on the most pressing sector issues and topics, with workshops, panels and plenary sessions covering:

• Doing business in Japan
• Gene therapy manufacturing and commercialization
• Clinical progress in immuno-oncology
• Gene editing
• The impact of a new healthcare model and what do payers think of gene therapies
• Financing gene and cell therapies
• Addressing uncertainty in regenerative medicine
• Process improvement and accelerated CMC development
• FDA update on the Office of Cellular, Tissue and Gene Therapies
• Evolving regulatory science to support innovation
• and more

Throughout the two-day Partnering Forum, event participants can also attend presentations by more than 60 prominent publicly traded and emerging private companies, highlighting clinical and commercial progress in cell therapy, gene and gene-modified cell therapy, tissue engineering, biomaterials and more. In addition to their presentations, representatives from these organizations will also be available for one-on-one partnering opportunities throughout the conference.

Slate of presenting companies:
4D Molecular Therapeutics; Abeona Therapeutics; Adverum Biotechnologies; AGTC; Argos Therapeutics; Audentes Therapeutics; Avita Medical; Biostage; bluebird bio; Caladrius Biosciences; Calimmune; Capricor Therapeutics; Cells for Cells; Cellular Dynamics International; Celyad; Commence Bio; Cryoport Systems; CTI Clinical Trial & Consulting Services; Cynata Therapeutics; Dimension Therapeutics; DiscGenics; Editas Medicine; Fibrocell; GenSight; GenVec; Histogenics; Immusoft; Intellia Therapeutics; InVivo Therapeutics; Irvine Scientific; Juventas Therapeutics; Kiadis Pharma; MaxCyte; MEDIPOST America; Mesoblast; MolMed; Nohla Therapeutics; NovaHep; Orchard Therapeutics; Organovo; ORIG3N; Osiris Therapeutics; Oxford BioMedica; Pluristem Therapeutics; Precision Biosciences; Promethera Biosciences; Regencor; Regeneus; ReNeuron Group; Sangamo BioSciences; SCM Lifescience Co.; Scottish National Blood Transfusion Service; StemBioSys; Stem Cell & Device Laboratory; Synpromics; Terumo BCT; Thermo Fisher Scientific; TiGenix; ToolGen; TrakCel; TxCell; Universal Cells; Vericel Corporation; ViaCyte; Vitruvian Networks; Voyager Therapeutics

Following the close of the Partnering Forum on October 6, there will be a Public Forum lecture and reception held at the Sanford Consortium for Regenerative Medicine, entitled "Stem Cells, a History of Freedom, Hope and Reality." Donna Skerrett, M.D., chief medical officer of Mesoblast, will introduce keynote speaker Elena Cattaneo, Ph.D., full professor, Laboratory of Stem Cell Biology and Pharmacology of Neurodegenerative Diseases, Department of Biosciences, University of Milan.

The Scientific Symposium held October 7 at the Salk Institute for Biological Studies will feature four panel discussions led by prominent international scientists and more than 35 posters featuring the latest scientific discoveries in the world of regenerative medicine and advanced therapies. The panels will cover recent advances on the use of human pluripotent stem cells to create organoids, and the insights into human development; cell therapy for hematopoietic disorders and beyond; genomics and genetics; and the use of stem/progenitor cell- and iPS cell-based systems for drug discovery, including CRISPR-based cell engineering, RNA splicing and patient cell-based drug discovery.

For full details on the agenda and further information about the event, please visit www.meetingonthemesa.com.

Registration is complimentary for investors and credentialed members of the media. For members of the media interested in attending, please contact ARM's Senior Director, Communications, Lyndsey Scull at lscull@alliancerm.org.

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 240 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.